Millennium Management LLC Cuts Holdings in RxSight, Inc. (NASDAQ:RXST)

Millennium Management LLC decreased its position in shares of RxSight, Inc. (NASDAQ:RXST) by 46.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 188,586 shares of the company’s stock after selling 166,168 shares during the period. Millennium Management LLC owned approximately 0.51% of RxSight worth $11,347,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC lifted its holdings in shares of RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after acquiring an additional 371 shares during the last quarter. Quest Partners LLC purchased a new position in shares of RxSight in the 2nd quarter worth approximately $41,000. Larson Financial Group LLC acquired a new stake in RxSight in the 1st quarter worth approximately $51,000. Amalgamated Bank boosted its stake in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in RxSight in the 2nd quarter worth approximately $156,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Insider Buying and Selling at RxSight

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,247,064.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 21,405 shares of company stock valued at $986,423 over the last 90 days. 9.36% of the stock is owned by insiders.

RxSight Trading Down 1.3 %

Shares of RXST stock opened at $48.24 on Tuesday. The company’s 50-day moving average price is $51.30 and its 200-day moving average price is $53.90. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -38.29 and a beta of 1.20. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company’s revenue was up 67.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) EPS. As a group, equities research analysts predict that RxSight, Inc. will post -0.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on RXST shares. Oppenheimer decreased their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus cut their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. BTIG Research upped their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Finally, Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.